Literature DB >> 15516980

The Phox2B homeobox gene is mutated in sporadic neuroblastomas.

Vera van Limpt1, Alexander Schramm, Arjan van Lakeman, Peter Sluis, Alvin Chan, Max van Noesel, Frank Baas, Huib Caron, Angelika Eggert, Rogier Versteeg.   

Abstract

Neuroblastomas are embryonal tumours of the sympatho-adrenal lineage with a clinical course ranging from spontaneous regression to fatal progression. The Phox2B homeobox transcription factor functions in the differentiation of the sympatho-adrenal lineage. Targets of Phox2B are, for example, genes of the (nor)adrenalin synthesis route, like Dopamine Beta Hydroxylase (DBH). Congenital Central Hypoventilation Syndrome was recently found to result from Phox2B mutations and two such patients in addition developed neuroblastoma. A germline mutation in Phox2B was identified in a family with hereditary neuroblastoma. Here, we report the first analysis of Phox2B in a series of 237 sporadic neuroblastomas and 22 cell lines. Six frameshift mutations were found in exons 2 and 3; including one in cell line SK-N-SH. Two patients showed de novo constitutional mutations. One of them was diagnosed with Haddad syndrome. All analysed cases expressed the mutated and wild-type Phox2B alleles. Ectopic expression of TrkA, the Nerve Growth Factor receptor, strongly downregulated Phox2B and DBH expression in cell line SH-SY5Y. However, TrkA and Phox2B showed a positive correlation in a panel of 66 neuroblastoma tumours. Although Phox2B mutations are infrequent (2.3%), they implicate a role for the Phox2B pathway in oncogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15516980     DOI: 10.1038/sj.onc.1208157

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  38 in total

1.  ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome.

Authors:  Franck Bourdeaut; Sandrine Ferrand; Laurence Brugières; Marjorie Hilbert; Agnès Ribeiro; Ludovic Lacroix; Jean Bénard; Valérie Combaret; Jean Michon; Dominique Valteau-Couanet; Bertrand Isidor; Xavier Rialland; Maryline Poirée; Anne-Sophie Defachelles; Michel Peuchmaur; Gudrun Schleiermacher; Gaëlle Pierron; Marion Gauthier-Villars; Isabelle Janoueix-Lerosey; Olivier Delattre
Journal:  Eur J Hum Genet       Date:  2011-11-09       Impact factor: 4.246

Review 2.  The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.

Authors:  Raquel Domingo-Fernandez; Karen Watters; Olga Piskareva; Raymond L Stallings; Isabella Bray
Journal:  Pediatr Surg Int       Date:  2012-12-29       Impact factor: 1.827

3.  Targeting MYCN in neuroblastoma by BET bromodomain inhibition.

Authors:  Alexandre Puissant; Stacey M Frumm; Gabriela Alexe; Christopher F Bassil; Jun Qi; Yvan H Chanthery; Erin A Nekritz; Rhamy Zeid; William Clay Gustafson; Patricia Greninger; Matthew J Garnett; Ultan McDermott; Cyril H Benes; Andrew L Kung; William A Weiss; James E Bradner; Kimberly Stegmaier
Journal:  Cancer Discov       Date:  2013-02-21       Impact factor: 39.397

4.  NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.

Authors:  Michael Hölzel; Sidong Huang; Jan Koster; Ingrid Ora; Arjan Lakeman; Huib Caron; Wouter Nijkamp; Jing Xie; Tom Callens; Shahab Asgharzadeh; Robert C Seeger; Ludwine Messiaen; Rogier Versteeg; René Bernards
Journal:  Cell       Date:  2010-07-23       Impact factor: 41.582

5.  Examination of PHOX2B in adult neuroendocrine neoplasms reveals relatively frequent expression in phaeochromocytomas and paragangliomas.

Authors:  John P Lee; Yin P Hung; Thomas M O'Dorisio; James R Howe; Jason L Hornick; Andrew M Bellizzi
Journal:  Histopathology       Date:  2017-07-13       Impact factor: 5.087

6.  Neuroblastoma phox2b variants stimulate proliferation and dedifferentiation of immature sympathetic neurons.

Authors:  Tobias Reiff; Konstantina Tsarovina; Afsaneh Majdazari; Mirko Schmidt; Isabel del Pino; Hermann Rohrer
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

7.  MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development.

Authors:  Goleeta Alam; Hongjuan Cui; Huilin Shi; Liqun Yang; Jane Ding; Ling Mao; William A Maltese; Han-Fei Ding
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

8.  PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma.

Authors:  Tiziana Bachetti; Daniela Di Paolo; Simona Di Lascio; Valentina Mirisola; Chiara Brignole; Marta Bellotti; Irene Caffa; Chiara Ferraris; Michele Fiore; Diego Fornasari; Roberto Chiarle; Silvia Borghini; Ulrich Pfeffer; Mirco Ponzoni; Isabella Ceccherini; Patrizia Perri
Journal:  PLoS One       Date:  2010-10-01       Impact factor: 3.240

9.  Mutations that disrupt PHOXB interaction with the neuronal calcium sensor HPCAL1 impede cellular differentiation in neuroblastoma.

Authors:  W Wang; Q Zhong; L Teng; N Bhatnagar; B Sharma; X Zhang; W Luther; L P Haynes; R D Burgoyne; M Vidal; S Volchenboum; D E Hill; R E George
Journal:  Oncogene       Date:  2013-07-22       Impact factor: 9.867

10.  Autonomic neurocristopathy-associated mutations in PHOX2B dysregulate Sox10 expression.

Authors:  Mayumi Nagashimada; Hiroshi Ohta; Chong Li; Kazuki Nakao; Toshihiro Uesaka; Jean-François Brunet; Jeanne Amiel; Delphine Trochet; Teruhiko Wakayama; Hideki Enomoto
Journal:  J Clin Invest       Date:  2012-08-27       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.